UPDATE: Milestone Pharmaceuticals (MIST) - CARDAMYST is on the Shelf. The Clock Starts Now.
Inventory is live at retail pharmacies. The sales force hits the street in mid-February. Here is the one number that matters.
The News: The Pocket Hospital is Open for Business
In an 8-K filing on January 26, 2026, Milestone Pharmaceuticals confirmed that the commercial engine has officially started.
The Details:
Status: CARDAMYST is available now at U.S. retail pharmacies.
The Push: The national sales force is hired but won’t fully deploy until mid-February.
The Price Strategy: Milestone announced an expected $25 copay cap for eligible commercially insured patients.
Why This Matters (Fighting the Step-Edit Bear)
In my Deep Dive from December, I identified a critical risk: Commercial Friction. There is a risk that insurers might force patients to fail cheap generic pills (diltiazem/verapamil) before paying for a branded nasal spray.
Today’s news offers the first defense against that risk.
The $25 Cap: By subsidizing the copay down to $25, Milestone removes the financial hesitation for the patient. If the doctor prescribes it, the patient is less likely to abandon the script at the counter due to sticker shock.
The Mid-February Lag: Note the gap between “availability” (today) and “sales force deployment” (mid-Feb). Do not panic if prescription numbers are low for the next 3 weeks. The drug is on the shelf, but the reps haven’t started selling it to doctors yet.
What to Watch: The NBRx Count
The Scientific Risk is over. The Financial Risk is covered. We are now in Execution Risk territory.
Starting in March, we need to watch the weekly New-to-Brand Prescriptions (NBRx) data.
Bull Signal: Steady week-over-week growth starting in late February.
Bear Signal: Flat scripts despite the $25 copay card (indicating doctors aren’t biting).
Thesis Status: Long / Buy. The company is executing the playbook exactly as promised. Now we wait for the scoreboard.
Not Financial Advice. Not Medical Advice. Do Your Own Diligence.